(Q85788043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

B Abila

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Cunningham

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Simeoni

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

16 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

163-169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

Is stroke the most common cause of disability?

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Acute ischemic stroke treatment in 2007.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Repairing the human brain after stroke. II. Restorative therapies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Emerging functions of myelin-associated proteins during development, neuronal plasticity, and neurodegeneration

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Selective neuronal loss in rescued penumbra relates to initial hypoperfusion.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Antibodies to myelin-associated glycoprotein accelerate preferential motor reinnervation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Pharmacokinetic aspects of biotechnology products

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Total neuropathy score: validation and reliability study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.227

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23267856%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference